SINOVAC Sinovac Hepatitis A and Chickenpox Vaccines Approved in Peru
桃花朵朵149
发表于 2024-9-3 10:25:47
1282
0
0
On September 3rd, SINOVAC announced on its official WeChat account that the company's inactivated hepatitis A vaccine, Hailaifu, has been released; reg; The children's and adult dosage forms, as well as the varicella attenuated live vaccine, have recently received registration approval from the Peruvian Medicines, Devices and Medicines Council (DIGIMID), both of which are the first approved Chinese hepatitis A vaccine and varicella attenuated live vaccine in Peru.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
You may like
- Merck's response to shortage of hepatitis A vaccines: new batches have entered circulation and supply this month
- The second flagship product is here! FDA approves Modena RSV vaccine
- What is the solution to the dilemma of domestic production of the nine valent HPV vaccine from "people waiting for vaccines" to "vaccines waiting for people"?
- Suddenly skyrocketing by 60%! Monkeypox concept stocks rise again, WHO urges to increase vaccine production
- Monkeypox vaccine after weight loss pills: why this Nordic country always dominates key drugs
- The number of infected cases has surged! US FDA approves Pfizer and Modena's updated COVID-19 vaccine
- Modna mRNA respiratory syncytial virus vaccine approved for market in the European Union
- Sanofi suspends flu vaccine supply? Hualan vaccine and Jindike hit the daily limit up, a response has been received
- Smallpox vaccine approved by FDA for preventing monkeypox infection, causing a huge shock in Emergent's stock price
- COVID-19 Star Vaccine Enterprise Reduces US $1 Billion R&D Investment in China with Increased Uncertainty